FDA’s Hormone Therapy Update Leads to Estrogen Patch Shortage
The FDA’s recent decision to lift the ‘black box warnings’ on hormone replacement therapy (HRT) has led to a shortage of estrogen patches. This change, initiated in November 2025, has raised concerns, especially among menopausal women who rely on HRT for relief from hot flashes and to support bone health. Dr. Janette Nesheiwat highlighted the essential role of HRT for millions, emphasizing the importance of ensuring access to these critical medications.
PCOS Rebranded as PMOS
In a significant update for women’s health, polycystic ovarian syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS). This new name was introduced by a team of global experts and published in The Lancet medical journal. The change was unveiled at the European Congress of Endocrinology in Prague.
Experts argued that the term PCOS is misleading, as it suggests that the condition is only about ovarian cysts. In fact, it encompasses a broader range of hormonal and metabolic concerns. The misinterpretation of PCOS could lead to delays in diagnosis and ongoing challenges for those affected.
The new terminology, PMOS, was agreed upon with input from over 56 health organizations and feedback from more than 14,000 individuals facing this condition. This name reflects the multiple hormonal and metabolic issues associated with the syndrome.
Understanding PMOS
PMOS affects approximately one in eight women and is being diagnosed with increasing frequency. Symptoms can include irregular menstrual cycles, weight gain, excessive hair growth, acne, and difficulties with conception.
Experts also note that PMOS can be linked to chronic inflammation, which might worsen insulin resistance, underscoring the need for awareness and proper care.
While there is no definitive cure for PMOS, various treatments can assist in managing its symptoms, helping women lead healthier lives.
